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Introduction
In previous work (1), we have demonstrated the feasibility of  in vivo imaging of  the whole-body CD4 pool 
of  simian/human immunodeficiency virus–infected (SHIV-infected) nonhuman primates (NHPs) using 
a radiolabeled humanized nondepleting anti-CD4 mAb (hu-IgG4/OKT4A) and single-photon emission 
CT (SPECT). Strong correlations (ρ > 0.75) were noted between radiotracer uptake in spleen, tonsil and 
axillary lymph nodes (LNs), and peripheral blood (PB) CD4+ T cell counts. Minimal uptake was noted 
in the gastrointestinal tract. These data highlighted the limitations of  using the PB CD4+ T cell counts 
to infer the level of  whole-body immunocompetence and challenged the prevalent notion that the gut is 
the major reservoir of  CD4+ T cells in the body. It has been suggested that the increases in the numbers 
of  CD4+ T cells in the PB of  HIV-1–infected subjects after initiation of  combination antiretroviral ther-
apy (cART) result from a combination of  2 phenomena: decreases in immune activation leading to an 
increase in distribution of  cells from lymphoid tissues (LTs) to PB, and increases in the total number of  
CD4 cells in the body due to a decrease in cell death (2). Determination of  the relative contributions of  
these 2 components requires simultaneous and repeated measurements of  both PB and total LTs. This 
is now possible through the use of  PB sampling and noninvasive, total body imaging with CD4-specific 
probes. Initial longitudinal imaging studies to examine the effects of  cART were compromised due to 
the immunogenicity of  the probe (1). Accordingly, the probes were modified from intact antibodies into 
F(ab′)2 fragments that were then coupled with the γ emitter 
99mTechnetium (99mTc) without loss in binding 
The peripheral blood represents only a small fraction of the total number of lymphocytes in the 
body. To develop a more thorough understanding of T cell dynamics, including the effects of SIV/
SHIV/HIV infection on immune cell depletion and immune reconstitution following combination 
antiretroviral therapy (cART), one needs to utilize approaches that allow direct visualization of 
lymphoid tissues. In the present study, noninvasive in vivo imaging of the CD4+ T cell pool has 
revealed that the timing of the CD4+ T cell pool reconstitution following initiation of ART in SIV-
infected nonhuman primates (NHPs) appears seemingly stochastic among clusters of lymph nodes 
within the same host. At 4 weeks following initiation or interruption of cART, the changes observed 
in peripheral blood (PB) are primarily related to changes in the whole-body CD4 pool rather than 
changes in lymphocyte trafficking. Lymph node CD4 pools in long-term antiretroviral-treated and 
plasma viral load–suppressed hosts appear suboptimally reconstituted compared with healthy 
controls, while splenic CD4 pools appear similar between the 2 groups.
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affinity to CD4 receptors. Utilizing F(ab′)2 fragments of  the humanized CDR-OKT4A/huIgG4 and of  the 
rhesus recombinant CD4R1-OKT4A/rhIgG1 mAbs, hereafter called F(ab′)2-OKT4A and F(ab′)2-CD4R1, 
respectively, longitudinal studies became possible, as recently demonstrated by our group in the settings 
of  hematopoietic stem cell transplantation following total body irradiation in NHPs (3). These modified 
radiotracers produced images with lower background compared with the intact mAb and considerably less 
immunogenicity than the intact antibodies. The current work examines longitudinal changes in the CD4 
pool in SIV-infected NHPs following the initiation or interruption of  cART.
Results
The in vitro and ex vivo specificity tests and the in vivo stability and biodistribution studies were performed 
for both the 99mTc-F(ab′)2-OKT4A, and the 
99mTc-F(ab′)2-CD4R1 radiotracers, as previously described (1, 
3). These preliminary studies showed high immunoreactivity and optimal stability of  both probes, as 
reported in Supplemental Figure 1 (supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.97880DS1).
Relationships between LTs and PB CD4 pools in SIV-infected NHPs. A summary of  the imaging experi-
ments and characterizations of  the monkeys imaged are shown in Supplemental Table 1. Eleven NHPs, 
spanning a range of  CD4+ T cell counts from 28–1,324, received 6.04 ± 1.27 mCi of  99mTc-F(ab′)2-OK-
T4A, and 19 NHPs, spanning a range of  CD4+ T cell counts from 7–1,718 cells/μl, received 6.12 ± 1.07 
mCi of  99mTc-F(ab′)2-CD4R1 i.v. after fasting for at least 8 hours. No association was found between the 
mean fluorescence intensity (MFI) of  CD4 cells in the PB and the PB CD4+ T cell count (not shown). 
Therefore, any differences in probe binding likely reflected differences in total numbers of  cells rather 
than differences in the number of  antibody molecules bound per cell. Whole-body SPECT images were 
acquired from the top of  the skull to the inguinal region for all animals at 4–6 hours after radiotracer injec-
tion (p.r.i.) and, for a subgroup of  animals, also at 19 hours p.r.i. The semi-quantitative analyses of  the 
3D-SPECT images are here summarized for all the images acquired at 4–6 hours p.r.i. Whole-body region 
of  interest (ROI) analyses revealed no significant correlations between PB CD4+ T cell count and hepatic 
uptake (OKT4A: ρ = –0.04, P = 0.46, n = 11; CD4R1: ρ = –0.21, P = 0.20, n = 19). In contrast, strong 
correlations were found between the radiotracer retention in LTs and PB CD4+ T cell count (Table 1 and 
Figure 1). The highest Spearman rank correlations were noted for the spleen (ρ > 0.70, P < 0.01), followed 
by the axillary and submandibular LNs (ρ > 0.52, P <0.05), suggesting that the majority of  the radiotracer 
uptake in these organs is the result of  specific binding of  the radiotracer to CD4+ cells. Moreover, nonsta-
tistically significant associations were observed between radiotracer uptake in kidney, heart, thymus, and 
bone marrow (proximal and central humerus) and PB CD4+ T cell count, suggesting that the majority of  
the radiotracer uptake in those organs was the result of  nonspecific uptake. This pattern of  correlations, or 
lack thereof, was also observed with the SUVmax and, overall, were found to be remarkably similar to those 
reported for the parent radiotracer 111In-DTPA-CDR-OKT4A/huIgG4 (1). Moreover, similar to what was 
observed with the intact anti-CD4 mAb, the SPECT imaging or direct radioactivity measurements of  any 
Table 1. Spearman rank correlation between peripheral blood CD4+ T cell count and organ radiotracer uptake
F(ab′)2-OKT4A (n = 11) F(ab′)2-CD4R1 (n = 19)
Spearman rank correlation P value Spearman rank correlation P value
Spleen 0.7 <0.01 0.76 <0.01
Axillary LNs 0.71 <0.01 0.55 <0.01
Submandibular LNs 0.61 0.02 0.52 0.01
Inguinal LNs 0.49 0.06 0.61 <0.01
Heart 0.45 0.08 0.21 0.19
Kidney 0.44 0.09 0.32 0.09
Bone marrow –0.25 0.77 0.11 0.33
Thymus 0.49 0.06 0.15 0.27
Plasma SUV 0.11 0.37 0.11 0.32
Spearman rank correlation between peripheral blood CD4+ T cell count and organ radiotracer uptake (radiotracer retention). The retention of radiotracer for 
each VOI was obtained from the maximum activity in the VOI normalized on the maximum activity in the liver.
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subcompartment (jejunum, ileum, and ascending and descending colon) of  the small and large intestine 
did not reveal differences between animals with high and low CD4+ T cell counts (see below and Supple-
mental Figures 2 and 5), with the overall uptake in these ROI close to background levels, consistent with 
the low density of  lymphocytes per unit mass of  these organs. Similar distributions of  the tracer, but with 
less contrast, were observed from the images acquired at 19 hours p.r.i.
The 30 (12 uninfected and 18 SIV/SHIV-infected) rhesus macaques imaged in this study received a 
total of  59 SPECT imaging studies (Supplemental Table 2). A repeated measurements univariate anal-
ysis of  all animals revealed that PB CD4+ T cell count was statistically significantly associated with the 
size of  the splenic CD4 pool and (in SIV-infected animals) the plasma viral load (both P < 0.001). The 
PB CD4+ T cell count was also univariately associated with the size of  the CD4 pool of  the axillary, 
inguinal, and submandibular LNs in all animals (all P < 0.01). The size of  the submandibular pool was 
also associated with the plasma viral load in infected animals (P = 0.046). In a multivariate analysis 
among the infected animals, adjusting for the PB CD4+ T cell count, only the size of  the splenic CD4 
pool remained associated with the plasma viral load (P = 0.01). For animals with similar PB CD4+ T 
cell counts, a 1-log increase in plasma viremia was associated with approximately an 8% depletion of  
the splenic CD4 pool.
Similar to what was observed with the intact mAb (1), the relationship between the CD4+ T cell count in 
the PB and the retention (or uptake) of  radiotracer in LTs appeared to be nonlinear (Supplemental Figure 3), 
suggesting that smaller changes in tissue CD4 pools are expected at higher levels of  PB CD4+ T cell counts.
Among the 30 animals imaged in this study, 11 healthy uninfected animals (with PB CD4+ T cell count 
>600 cells/μl) were imaged at baseline; 10 animals with advanced SIV or SHIV infection (CD4+ T cell count 
<300 cells/μl) were imaged during the chronic phase of  infection (> 5 months from viral inoculation); and 
6 animals with SIV infection were imaged after being treated with cART for more than 5 months (plasma 
SIV RNA levels <30 copies/ml in 5 animals and 950 copies/ml in the other). Compared with healthy unin-
fected controls (n = 11, mean PB CD4+ T cell count 962 cells/μl, 95% CI, 773–1,151 cells/μl), long-term 
Figure 1. Cross-sectional comparison of LTs uptakes. Maximum intensity projection–single-photon emission CT (MIP-SPECT) images in the abdom-
inal (A) or skull (B) field of view (FOV) in monkeys characterized by different peripheral blood CD4 cell counts. Top panels: animals were imaged with 
99mTc-F(ab′)2-CD4R1. Bottom panels: animals were imaged with
99mTc-F(ab′)2-OKT4A. All images are adjusted between monkeys on the maximum liver 
uptake. Tissue uptakes were converted to rainbow color scale as shown in the color bar, where red indicates highest retention.
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cART-treated animals (n = 6, mean PB CD4 count: 691 cells/μl, 95% CI, 235–1,147 cells/μl) had smaller 
axillary (P < 0.05) and inguinal (P < 0.05) LN CD4 pools but similar levels of  submandibular and splenic 
CD4 pools (Figure 2). The suboptimal reconstitution of  these clusters of  LNs during long-term antiretroviral 
treatment is not consistently revealed by the PB CD4+ T cell count, as can be seen for the SIV cART-treated 
animal P881 (Figure 3). Compared with advanced, chronically infected, and untreated animals (10 animals, 
14 measurements, mean PB CD4+ T cell count, 137 cells/μl; robust sample size adjusted GEE 95% CI, 
87–186 cells/μl) (4, 5), the long-term treated animals had statistically significantly higher splenic and sub-
mandibular CD4 pools (linear mixed effects model, P < 0.01) but similar levels of  axillary and inguinal CD4 
pools (Figure 2).
As evident from Figure 2, one animal in the treated group showed a supranormal level of  CD4 
pools in the axillary and inguinal LNs, about 2.5-fold higher than the healthy uninfected controls. Inter-
estingly, this animal (P887) had a very high nadir PB CD4 count during the chronic phase of  infection 
prior to initiation of  cART (852 cells/μl compared with 43–498 cells/μl in the remaining 5 animals). 
Similarly, this supranormal level of  CD4 pool in LNs was also observed in animals DCBP and P707, 2 
SIV-infected animals with a long-term nonprogressor phenotype (Supplemental Table 1).
Relationships between LTs and the PB CD4 pool in SIV-infected NHPs following the initiation or interruption of  
cART. We next examined longitudinal changes in the images of  the whole-body CD4 pool during admin-
istration of  ART to a group of  7 SIV-infected animals. Five chronically SIV-infected animals (P248, H755, 
P246, P261, and P247) were imaged at baseline and at different time points following initiation of  cART 
with 99mTc-F(ab′)2-OKT4A. Similarly, 2 additional chronically SIV-infected animals (P844 and P773) were 
imaged at baseline and at different time points following initiation of  cART with 99mTc-F(ab′)2-CD4R1. The 
specific probes used for each imaging session and the imaging time points are indicated in Supplemental 
Table 2. Plasma samples were collected at each imaging time point and screened for immunogenicity to the 
probe. Data were excluded from the analyses if  the animals developed an antibody response to the probe 
(Supplemental Data, Supplemental Figure 4). 
As shown in the lower panels of Figure 3 and as expected, cART led to reductions in SIV RNA levels and 
increases in PB CD4+ T cell counts in all animals. During the first month of therapy, the increase in PB CD4+ T 
cell counts (mean 120 cells/μl; 95% CI, –31 to 271 cells/μl) was concomitant to a statistically significant increase 
Figure 2. Comparison between the CD4 pools of healthy, infected, untreated, and cART-treated animals. CD4 pools 
in 3 groups of animals: uninfected healthy controls with PB CD4+ T cell count > 600 cells/μl (black), advanced SIV 
chronically infected animals with PB CD4+ T cell count < 300 cells/μl (blue), and SIV-infected long-term cART-treated 
(>5 months) nonhuman primates (red). Two animals in the group of SIV chronically infected animals were later treat-
ed with cART for more than 5 months: P246, who had 3 baseline scans during the chronic phase of infection (blue 
open circles) and before treatment (red open circle), and H755, who had 2 baseline scans during the chronic phase of 
infection (blue diamond with center dot) and was then reimaged after long-term treatment (red diamond with center 
dot). Another animal, P773, had 2 baseline scans during the chronic phase of infection (blue hexagon). Ax, axillary; 
Ing, inguinal; LN, lymph node; Sub, submandibular.
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in the splenic pool of CD4+ T cells (mean 19.6%, 95% CI, 2.6%–36.6%) (P < 0.05, n = 7). In the following 
months, however, additional increases in CD4+ T cell counts were associated with variable degrees of change in 
tissue retention of tracer. In 2 animals (P248 and P261), there were marked increases of the CD4 pools in specif-
ic clusters of LNs with little change in splenic uptake. These 2 hosts also revealed an unexpected dynamic, with 
CD4+ T cell reconstitution appearing in different LTs at different times. In P844, there was a marked increase in 
splenic uptake with no change in LN CD4 pools. Other animals (H755, P246, and P773) showed increases in 
both LNs and spleen. Overall, this group of animals illustrate that the dynamics of CD4 repopulation in LTs are 
only approximated by the dynamics of CD4 repopulation in the PB and that the reconstitution is highly hetero-
geneous not only among hosts, but also within different anatomic compartments of the same host.
As an example, animal H755 (Figure 3 and Figure 4) showed a rapid increase in the PB CD4 count 
during the first 4 weeks following initiation of  cART, which then stabilized throughout the period of  
follow up to low levels (~300 CD4+ T cells/μl). Surprisingly, the LTs showed a gradual repopulation 
that achieved close-to-normal levels within 1 year of  follow up. In this case, the whole-body repopula-
tion of  the CD4 pool continued, despite a rapid plateau achieved in the PB compartment.
We next examined the changes in the CD4 pool following interruption of  cART in 2 chronically 
SIV-infected animals. Animal P881 received cART for ~19 months, which led to a decrease in plasma 
viremia from ~5 log to <15 SIV RNA copies/ml for ~ 1 year prior to interruption of  therapy. At the time 
of  therapy interruption, the PB CD4+ T cell count was above 1,300 cells/μl, and despite this normal PB 
CD4 count, splenic and LN CD4 pools were ~30%–40% of  healthy controls (Figure 3 and Figure 5). 
Following interruption of  cART, the PB CD4 count dropped during the first month by 34%, concomitant 
Figure 3. Whole-body dynamics of the CD4 pool, CD4+ T cell count, and plasma VL after cART initiation or interruption. 9 monkeys were studied longi-
tudinally following start of therapy or interruption. For each animal, top graph shows the relative radiotracer retention in lymphoid tissues calculated with 
respect to the mean levels measured in a group of healthy controls (horizontal dashed line), and bottom graph shows CD4+ T cell count in the peripheral 
blood (cells/μl) and SIV RNA (copies/ml) in plasma. Day 0 indicates the start of therapy or interruption.
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with a 33% decrease in the splenic CD4 pool. Similarly, animal P731 received cART for ~18 months 
with a reduction in plasma viremia from ~4 log to <10 SIV RNA copies/ml for 1 year prior. At the time 
of  therapy interruption, the PB CD4 T cell count was 355 cells/μl. The sizes of  the splenic and most of  
the LN CD4 pools were below those of  healthy controls (Figure 3). Surprisingly, following interruption 
of  cART, we observed an increase (instead of  a decrease) in CD4+ T cell count 6 weeks following inter-
ruption of  cART. This was accompanied by an increase in the splenic CD4 pool, with no appreciable 
changes in LN CD4 pools. The LTs did not show evidence of  CD4 depletion during the following 2 
months of  therapy interruption, during which time plasma viral load remained below ~3 log.
Images of  gut CD4 pool. Similar to what has been observed in our previous studies (1, 3), using 
either the 99mTc-F(ab′)2-OKT4A or the 
99mTc-F(ab′)2-CD4R1 radiotracers, no differences were noted in 
the analyses of  the 3D SPECT images of  the intestines between healthy and SIV-infected CD4-depleted 
animals. This was despite observing significant differences in probe uptake in LNs and the spleen.
To further examine the relative uptake of  the tracer in the LTs, we harvested LNs, splenic tissue, 
and gut tissue from control and CD4-depleted animals for ex vivo imaging following in vivo admin-
istration of  probe. Two groups of  animals, each group consisting of  1 healthy and 1 SIV-infected 
animal, were necropsied at 6 hours or 21 hours p.r.i., respectively, and organs were harvested for 
radioactive measurements. The organs were placed on a tray and imaged with the SPECT camera 
(Supplemental Figure 5 for the 6-hour p.r.i. necropsy, and Figure 6 for the 21-hour p.r.i. necropsy). As 
can be seen from the planar images of  the trays in Figure 6, isolated discrete areas of  high radiotracer 
uptakes can be seen in both the healthy and infected animals, with few of  these discrete spots reaching 
levels similar to the uptake in the LNs. Of  note, in the healthy animal, we identified 4 hot areas, with 
3 of  them localizing in the mesenteric compartment but not in the intestines. Overall, LN uptake was 
~15-fold lower in the CD4-depleted animals compared with the controls. Few, if  any, differences in gut 
radioactivity were observed between the healthy and the CD4-depleted animals.
Discussion
Fewer than 2% of  the total number of  lymphocytes in the body reside in the PB at any time (1). Small 
changes in the distribution of  lymphocytes between PB and tissues can have a significant impact on 
the number of  CD4+ T cells measured in 1 μl of  blood. Hence, in vivo imaging technologies of  the T 
cell pools may be able to provide a more robust quantitative analysis of  the T cell pool under specific 
perturbations of  the quasi-steady state of  the immune system.
After describing the feasibility of  imaging the CD4 pool in vivo using SPECT and an intact anti-CD4 
mAb labeled with 111Indium in healthy and SHIV-infected animals, our group has recently used the modi-
fied anti-CD4 radiotracer presented in this study (99mTc-F(ab′)2-CD4R1) to image the whole-body CD4 pool 
following conditioning regimen and autologous stem cell transplantation in rhesus macaques (3). These first 
studies also provided ex vivo measurements to validate the use of  this noninvasive in vivo imaging system to 
infer the total number of  CD4 cells in anatomic compartments. We provided evidence that the radiotracer 
uptake is proportional to the number of  CD4 receptors per unit volume of  tissue only in clusters of  axillary, 
Figure 4. cART-induced splenic CD4 pool repopulation in a poor immunologic responder. Dynamics of cART-induced 
CD4 repopulation of the spleen in the SIV-infected animal H755. All images are adjusted on the maximum liver uptake. 
Dashed lines indicate spleen regions of interest.
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submandibular, and inguinal LNs, and in the spleen (i.e., in lymphoid organs with sufficient densities of  
CD4 receptors [number of  receptors per unit volume] to be detected above background levels using this 
imaging system). Because, in these organs, more than 90% of  the uptake was found to be the result of  spe-
cific binding, it was possible to observe differences in these organs following perturbations of  the immune 
system (e.g., after SIV infection or after initiation of  ART) within a range of  ~10-fold maximum differenc-
es between healthy and severely CD4-depleted animals. Conversely, in anatomic compartments with low 
densities of  CD4 cells, the majority of  the probe uptake is nonspecific; therefore, no correlation is observed 
Figure 5. Images of CD4 pools following initiation or interruption of cART. LT CD4 pool dynamics following initiation (A and B) or interruption (C) 
of cART in 2 SIV-infected nonhuman primates. All images are adjusted within and between monkeys on the maximum liver uptake (for SPECT). 
Different image contrasts were applied to head and abdominal field of views (FOV) in SPECT image to highlight clusters of LNs and spleen. Tissue 
uptakes were converted to RAINBOW color scale as shown in color bar, where red indicates highest retention.
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between the latter and the state of  immunodeficiency of  the host. An example is the PB, in which the num-
ber of  CD4 cells per unit volume can be 100 fold or more different between healthy and SIV-depleted ani-
mals, yet no difference in anti-CD4 probe uptake is observed throughout the imaging biodistribution period.
The new radiotracers produced higher quality images of  the whole-body CD4 pool due to the 
lower backgrounds. The highest levels of  radiotracer uptakes were observed in the clusters of  LNs and 
in the spleen of  healthy animals, and — similar to the intact anti-CD4 mAb — these were positively 
correlated with the PB CD4+ T cell count. Moreover, as expected, no correlations were found between 
the radiotracer uptake in organs of  clearance (e.g., kidney and liver) and the PB CD4+ T cell count. In 
vivo and ex vivo radioactivity data did not reveal differences in anti-CD4 radiotracer uptake in the gut, 
despite changes in PB CD4 counts.
The transplant study also showed that dramatic fluctuations of  the number of  CD4+ T cells in the PB 
can occur by forcing the release of  lymphocytes from the LTs to the PB with agents such as the CXCR4 
receptor antagonist AMD3100, without detectable changes in the whole-body CD4 pool. This observation 
is consistent with a small percentage of  CD4+ cells in tissues being released from tissues to PB following 
AMD3100 administration and highlights the importance of  whole-body CD4 imaging to assess the etiolog-
ical factors behind the fluctuations of  CD4 cells in the PB; therefore, the use of  this technology is particu-
larly important when we perturb the immune system with immunotherapeutic strategies that are known to 
interfere with homing and trafficking of  lymphocytes in the body.
In vivo imaging of  the CD4 pool has recently been used to help discern the effects of  an anti–α4β7 
mAb on the SIV reservoir and CD4 pool (6), an example of  immunotherapeutic strategy that is expected to 
perturb trafficking of  lymphocytes between tissues and PB. In that study, using the same antibody fragment 
Figure 6. Ex vivo imaging of the gut. One healthy (A) and 1 SIV-infected (B)animal were necropsied at 21 hours p.r.i. The entire jejunum and entire ileum 
(>95% of the small intestines) and entire colon laid on a tray with a portion of the mesentery (~50% of the entire mesentery) attached to the intestine 
walls. The mesentery is a double fold of peritoneum, fan-shaped, which covers the entire length of the jejunum and ileum. Between the 2 leaves of the 
mesentery are the mesenteric vessels, fat, and mesenteric lymph nodes. Tissue uptakes normalized on plasma levels were converted to RAINBOW color 
scale as shown in color bar, where red indicates highest uptake.
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utilized in this study and in our previous work (3), the authors noted similar biodistribution of  the probe in 
the LNs and spleen but noted a high uptake of  the probe in the gut of  healthy animals from in vivo imaging 
data (with a mean probe uptake throughout the gut similar to the probe uptake in the LNs). The reasons 
behind this striking difference between that study and our observations are unclear but may include the use 
of  different radiolabeling procedures (99mTc versus 64Cu), different biodistribution periods (21 hours versus 
36 hours), or use of  a higher (~100 μg versus ~1 mg) dose of  tracer leading to differential organ-specific 
penetration of  the probe (Supplemental Data, and Supplemental Figures 7–9). Alternatively, the high gut 
uptake reported in Byrareddy et al. (6) could be primarily explained by uptake in mesenteric LNs (in prox-
imity to the intestinal walls) as opposed to the gut. The mesenteric LNs are distributed in a larger volume of  
interest (VOI) compared with the clusters of  axillary, inguinal, or submandibular LNs, hence the 2 sets of  
studies may be reconciled by the differential spatial resolutions of  the in vivo imaging technologies adopted 
(PET superior to SPECT), as could be revealed by ex vivo measurements of  the intestines harvested on 
a tray in which the contribution of  mesenteric LNs would be minimized. In order to address this major 
discrepancy between the 2 sets of  studies, we have studied the biodistribution of  the 64Cu anti-CD4 probe 
and found that the 64Cu and the 99mTc probes show similar biodistributions (from ex vivo measurements) 
when injected at the same dose, excluding differential penetration as the major factor behind the differences 
observed in the 2 studies and providing evidence that the mean uptake of  the probes in the intestinal walls 
is about 10-fold lower than the probe uptake in the LNs (Supplemental Figure 9). Consistent with our con-
clusions, dose-escalating studies of  a different anti-CD4 fragment probe to image the CD4 pools, recently 
described in rodents (7), showed that, despite increasing the total mass of  the probe injected, the relative 
uptake in the small and large intestines remains low and ~50-fold lower than the relative probe uptake in 
spleen and clusters of  LNs. To fully resolve this important discrepancy, dose-escalating studies in NHPs of  
the anti-CD4 probe are needed to optimize the dose administration for the CD4 pool imaging system in 
large hosts (8), as well as to confirm the nature of  the probe uptake in the gut ROI. The generation of  an 
input function and time activity curve for a precise estimate of  the binding potential for CD4 receptors in 
the organs of  interest are needed to reconcile these observations and to identify the optimal dose and timing 
of  imaging, for the efficient translation of  this technology to human studies (9).
The imaging system in the present study highlighted a nonlinear relationship between the PB and LT 
pools of  CD4+ T cells similar to what was observed with the intact anti-CD4 mAb (1). One possible expla-
nation for this is that partition of  CD4 cells between PB and LT changes at different CD4 pool sizes. This 
explanation is consistent with previous observations in SIV-infected monkeys (10) in which more dramatic 
changes in the CD4 pool of  LNs have been reported to occur when the CD4+ T cell count in the PB falls 
below 200–300 CD4+ T cells/μl, suggesting that trafficking rates between PB and LTs are not constant but 
are governed by incompletely understood mechanisms, possibly related to lymphoid homeostasis.
The potentially novel anti-CD4 radiotracer used in this study cannot discriminate between CD4+ T cells and 
other CD4+ cells such as macrophages. The latter cells express CD4 at relatively low levels per cell compared 
with lymphocytes (11, 12). Moreover, the percentage of mononuclear cells (MNCs) that are macrophages is 
much lower than lymphocytes in spleen and LNs (13). Therefore, the contribution to the total binding sites for 
the radiotracer (i.e., CD4 receptors per unit mass/volume of tissue) brought by the macrophages/monocytes 
compartment is expected to be much lower than the contribution brought by the CD4+ T cells.
The fragmentation of  intact anti-CD4 mAbs into a less immunogenic tracer has also allowed longitudi-
nal imaging of  the CD4 pools in rhesus macaques infected with SIV following initiation and discontinua-
tion of  ART. As expected, in cross-sectional analyses of  quasi-steady states of  the immune systems of  hosts 
imaged at different phases of  disease progression, highly significant associations have been found between 
the PB CD4 count and the CD4 pools of  LNs and spleen. The imaging system also provided some evidence 
of  suboptimal reconstitution in specific clusters of  LNs, but not in the spleen, in the settings of  long-term 
cART-treated animals, including in 1 animal with normalized PB CD4 count. Interestingly, this slower 
reconstitution of  the CD4 pool in clusters of  LNs compared with spleen was also observed following total 
body irradiation and autologous stem cells transplantation. In that study, complete reconstitution of  the 
PB CD4+ T cell counts and splenetic CD4 pools were seen in a setting of  only 60%–70% recovery of  the 
LN CD4 pools. Of  note, SIV/SHIV infection appears to cause a more complete depletion of  the total body 
CD4 pool compared with medium to high doses of  total body irradiation (3).
This profound heterogeneity in immune reconstitution among anatomic compartments observed follow-
ing cART in the SIV model may reflect different degrees of damage and fibrosis to secondary lymphoid organs 
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with tissue-specific disruption of lymphoid repopulation (14). Alternatively, slower reconstitution in specific 
anatomic compartments could also reflect localized persistent residual immune activation, caused by residual 
viral production with or without de novo infection due to poor or suboptimal penetration of antiviral drugs to 
sanctuary sites such as LNs (15–17) or to the differential impact of foreign antigens in different LNs.
Interestingly, in a multivariate analysis with repeated measurements of  all infected longitudinally 
imaged animals, we found evidence that, after adjusting for PB CD4 counts, plasma viremia was still inde-
pendently associated with the CD4 pool of  the spleen but not with the CD4 pool of  the LNs.
The spleen is the largest reservoir of  lymphocytes in the body (1, 18). It is of  note that a statistically 
significant increase in the splenic CD4 pool was seen as early as 4 weeks after the initiation of  ART. These 
data indicate that the early phase of  increasing CD4+ T cell counts seen following initiation of  cART may 
be due to more than just changes in trafficking rates between LTs and PB. Similarly, the rapid declines in 
CD4+ T cell counts seen following discontinuation of  cART were immediately reflected in the spleen. 
Overall, gains (up to 37%) in the splenic CD4 pool happen as rapidly as losses (up to 30%) in the splenic 
CD4 pool 4 weeks following initiation or interruption of  cART, respectively.
Overall, our data suggest that the dynamics of  the CD4+ cell pool following initiation or interruption 
of  ART in SIV-infected NHPs are only approximated by the dynamics observed in PB CD4 counts and 
appear highly heterogeneous between and within hosts. A key example of  mismatch in the dynamics of  
cART-induced CD4 reconstitution between the PB and LT is offered by animal H755, in which a plateau in 
the number of  CD4 cells in the PB is reached several months earlier than the LT. This host also illustrates 
the fact that low CD4+ cell counts in the blood, does not exclude close-to-normal reversion of  HIV-induced 
immunodeficiency at the tissue level, suggesting that at least some of  the patients with treated HIV infec-
tion referred to as poor immunologic responders may in fact have normal immune systems at the tissue 
level (19). Applying these techniques of  in vivo imaging to humans would directly test this hypothesis.
Our data are also consistent with a seemingly stochastic pattern of LN regeneration following cART (i.e., 
changes in the CD4 pools of the LNs do not appear to be synchronous or homogeneous between hosts or with-
in anatomic compartments of the same host). In some animals, increases in the CD4 pool following initiation 
of cART take place in specific clusters of LNs but not in other clusters or in the spleen. In other animals, visible 
increases in the CD4 pool of LNs can be seen at month 1, while in other animals, longer treatment periods are 
needed for CD4 levels to increase. Whether irreversible or partially reversible LN elasticity induced by SIV rep-
lication in tissues is in part responsible for the seemingly stochastic LNs in CD4 pool reconstitutions deserves 
further investigation (20). Whole-body imaging–guided sampling of tissues in future longitudinal analyses may 
provide important insights on the etiological factors behind differential organ-specific reconstitution or deple-
tion of the T cell pools, following specific perturbations of the quasi-steady state of the immune system.
The sample size and limited number of  radiotracer administrations, due to the development of  immu-
nogenic response to the tracer, constitute the major limitations of  the current study. It is relevant to note 
that the outcome of  the in vivo imaging is a measurement for the receptor density of  an entire organ — 
therefore, less vulnerable to sampling variabilities. Based on consecutive imaging sessions, performed only 
a few weeks apart in animals at steady state, these measurements are quite reproducible (Figure 3). The 
extension of  this technology to imaging of  humans (e.g., through the radiolabeling of  fully humanized 
anti-CD4 mAb fragments; ref. 21) or the design of  nonimmunogenic low molecular weight anti-CD4 radio-
probes may help to better gauge the degree of  immune reconstitution following standard and experimental 
treatments of  HIV. Imaging of  the CD4 pool of  humans may allow for better evaluation of  immune recon-
stitution in the settings of  HIV infection and other conditions associated with CD4 depletion.
Methods
Preparation of 99mTc-labeled anti-CD4 tracers
Antibodies. Humanized anti-CD4 CDR-OKT4A/huIgG4 was produced from transfected NS0 cells as pre-
viously described (22). To produce rhesus recombinant antibody, CD4R1-OKT4A/rhIgG1, complemen-
tarity determining regions (CDRs) representing the anti-CD4 antibody OKT4A (23) were grafted onto a 
rhesus scaffold using rhesus germline variable region as templates. Key positions potentially contributing 
to antigen binding, CDR conformation, and heavy- and light-chain interactions were retained as the mouse 
residue (24). DNA representing recombinant variable heavy regions (VH) and variable light regions (VL) 
were synthesized, amplified by PCR, and purified from agarose gel with the QIAquick Gel Extraction Kit 
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(Qiagen). Recombinant fragment variable DNAs (Fv-DNAs) were subcloned into rhesus IgG1 constant 
heavy region (CH) and constant light region (CL) expression vectors as described above. For large-scale 
production of  rhesus recombinant antibodies, recombinant heavy- and light-chain vectors were packaged 
in retroviral vectors and used to infect CHO cells using the GPEx expression platform (Catalent Phar-
ma Solutions). Antibody was produced from a high-expressing transduced subclone, grown in serum free 
medium. After clarification, recombinant antibody was purified from supernatant by protein A affinity 
chromatography. The purified antibodies were placed in phosphate buffer, pH 6.5. Endotoxin levels were 
<1 EU/mg of  antibody.
Preparation of  F(ab′)2. We prepared F(ab′)2-OKT4A and F(ab′)2-CD4R1 by pepsin digestion according 
to the manufacture’s instruction (Pierce F(ab’)2 Preparation Kit, Thermo Fisher Scientific). Briefly, 20 mg 
of  CDR-OKT4A/huIgG4 (5 mg/ml) or CD4R1-OKT4A/rhIgG1 (5.1 mg/ml) was digested by pepsin 
immobilized on agarose gel (Thermo Fisher Scientific) in 0.1 M sodium acetate buffer (pH 4.4). The diges-
tion was performed at 37°C for 4 hours using an optimal antibody/pepsin weight ratio between 6.7:1 to 
10:1. After digestion, the reaction mixture was purified using Protein A-Sepharose affinity chromatography 
(Thermo Fisher Scientific), followed by dialysis in PBS using a dialysis membrane cassette with 20 kDa 
molecular weight cut-off  at 4°C for 22 hours. The purified protein was concentrated using a Centriprep 
YM-50 membrane (Amicon) to a concentration of  5.2 mg/ml. Protein purity was assessed by SDS-PAGE 
(Invitrogen) and size-exclusion HPLC (Gilson) equipped with a size-exclusion TSK gel G3000SWXL col-
umn (7.8 × 300 mm, 5 μm, TOSOH Bioscience; 0.067 M sodium phosphate/0.15 M sodium chloride with, 
pH 6.8; 1.0 ml/min) and a UV monitor.
Conjugation of  HYNIC to F(ab′)2-OKT4A and F(ab′)2-CD4R1. Succinimidyl-6-hydrazino-nicotinamide 
(HYNIC-NHS, Solulink) was freshly dissolved in DMF (5.2 mM). Ten times molar excess (200 μmol) of  
HYNIC-NHS was added to 2 mg (20 μmol) of  F(ab′)2 fragments in 0.4 ml of  0.0067 M PBS buffer (PBS 
1×), pH 7.2. The solution was stirred gently and incubated in a refrigerator at 4°C for 65 hours. The level 
of  HYNIC conjugation was estimated to be 3 HYNIC molecules per F(ab′)2 by the percent distribution of  
99mTc between HYNIC-F(ab′)2 and free HYNIC when analyzed by size-exclusion HPLC. The reaction mix-
ture was diluted 10 times with the same PBS and concentrated by Amicon 50K. The protein concentration 
was determined by the Bradford method. The conjugated product was stored in a freezer at –80°C until 
radiolabeling with 99mTc for imaging studies.
99mTc labeling. In a rubber-sealed vial, HYNIC-F(ab′)2-OKT4A or -CD4R1 (360 μg in PBS 1×) was 
incubated with 99mTcO4
−1 (40 mCi; 1480MBq) in 0.2 ml aqueous medium at pH 6 containing tricine (112 
mM, 20 mg/ml), sodium succinate (25 mM), and stannous chloride (82 μg/ml) at 37°C for 30 minutes. All 
reagents were freshly made in deionized water, which was deoxygenized by bubbling with N2 stream for 1 
hour. 99mTc labeled F(ab′)2 proteins were purified on PD-10 size-exclusion columns (GE Healthcare) eluted 
with PBS, pH 7.2. The radiochemical purity of  the 99mTc-labeled F(ab′)2 was determined by size-exclusion 
HPLC equipped with an on-line flow radioactivity detector (BioScan).
Immunoreactivty binding assays
The immunoreactivity of  the radiolabeled products was tested using a modification of  a cell-binding assay 
by Lindmo and Bunn (25), as previously described (1).
Animals study design
Healthy animals and SIV-infected animals before/after cART treatment, imaged with 99mTc-F(ab′)2-OKT4A. An out-
line of  the protocol design and the number of  adult monkeys (median age 6.2 years [5–13.8 years] and 
median weight 6.9 kg [5.4–11.8 kg]) imaged with the humanized 99mTc-F(ab′)2-OKT4A at different phases of  
lentiviral infection are shown in Supplemental Tables 1 and 2. Two uninfected female (CE7E, 01D278), 3 
uninfected male (CF67, XAW, DBPN), 1 SIV–thymidine kinase–infected (SIV-TK–infected) male (A5E036), 
1 SIVE543-infected male (H755), and 4 SIVmac251-infected females (P246, P261, P248, P247) Indian rhe-
sus macaques were imported in this study from 3 completed studies at NIH. The SIVmac251-infected ani-
mals were transferred from a study, and these animals received a recombinant vaccine containing canarypox 
vector–SIV (ALVAC-SIV) 1 year prior to importing them in our study (26). The SIV-TK–infected rhesus 
macaque was challenged i.v. with 1 × 105 TCID50 of  a recombinant SIVmac239 virus carrying the HSV-TK 
gene in Nef  and showed complete control of  viral load and high levels of  CD4 cell counts after the phase of  
acute infection. The SIVE543-infected rhesus macaque was challenged intrarectally with 1 × 103 TCID50 of  
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SIVsmE543-3 (27).The P246, P248, and P247 rhesus macaques were challenged with 1 × 104 TCID50 and 
the P261with 2.0 × 103 TCID50 of  SIVmac251, intravaginally. Following baseline imaging, the SIVE543-in-
fected animal and the 4 SIVmac251-infected animals were treated with cART: Tenofovir (PMPA) 20 mg/
kg + Emtricitabine (FTC) 50 mg/kg, s.c. once per day. All animals utilized in this study were maintained in 
accordance with the Guide for the Care and Use of  Laboratory Animals (28). They were housed in a bio-
safety level 2 facility, and biosafety level 3 practices were followed. Phlebotomies and virus inoculation were 
performed with animals anesthetized with ketamine/acepromazine.
Healthy animals and SIV/SHIV-infected animals imaged with 99mTc-F(ab′)2-CD4R1. An outline of the protocol 
design and the number of adult monkeys (median age: 4.2 years [3.1–9.9 years] and median weight: 5.4 kg 
[4.4–9.2 kg]) imaged with the rhesus recombinant 99mTc-F(ab′)2-CD4R1 are shown in Supplemental Tables 
1 and 2. Seven uninfected and 12 lentiviral (SIVmac251, SIVmac239, SHIVAD08, SHIVDH12R) chronical-
ly infected Indian rhesus macaques were recruited in this study. The SIVmac251-infected rhesus macaques 
were challenged intrarectally with 1 × 103 TCID50 of SIVmac251. The SHIV-infected rhesus macaque, DA24, 
was challenged intrarectally with 10 TCID50 of SHIVAD8 clone (29). The SIV-TK–infected rhesus macaque 
(A5e006) was challenged i.v. with 1 × 105 TCID50 of a recombinant SIVmac239 virus carrying the HSV-TK 
gene in Nef and showed complete control of viral load and high levels of CD4 cell counts after the phase 
of acute infection. The SHIVDH12R\SIVmac239 chronically infected rhesus macaque, G43, was challenged 
i.v. with 1 × 103 TCID50 of SHIVDH12R-clone 7 and 1 × 103 TCID50 of SIVmac239. Following baseline 
imaging, 2 SIVmac251-infected animals (P844 and P773) were treated with Tenofovir (PMPA) 20 mg/kg + 
Emtricitabine (FTC) 30 mg/kg s.c. once per day, and Raltegravir 20 mg/kg/BID mixed in food. The SIV-
mac251-infected animals (P881 and P731) were both treated with the same regimen when they were imaged at 
baseline, prior to interruption of cART.
Lymphocyte immunophenotyping and plasma viral RNA measurements
Virion-associated SIV RNA in plasma was measured using a quantitative PCR (qPCR) assay, essentially as 
described previously (30). Immunophenotyping of  EDTA-treated blood samples was carried out by using 
fluorochrome-conjugated mAb (anti–CD3-fluorescein isothiocyanate, 556611; anti–CD4-allophycocyan-
in, 340443; anti–CD8-peridinin chlorophyll protein, 347314; anti–CD20-phycoerytrin-CY7, 335793; and 
anti–Ki67-phycoerythrin, 556027; all BD Biosciences) and analyzed by flow cytometry (31).
Imaging and Biodistribution Studies (SPECT/CT)
The animals were anesthetized with ketamine (10 mg/kg) and acepromazine (VetOne) (0.1 mg/kg) and, after 
shaving the skin and prepping the insertion sites, a 22-gauge catheter was inserted in the saphenous vein of the 
leg for the administration of radiotracer or for administration of anesthetics during the imaging procedures. 
Anesthetized primates were monitored with pulse oxymeter and thermometer. Heating pads were used to main-
tain the animal’s body temperature during imaging. The arms and legs of the macaque were restrained, and 
the animals were positioned in the appropriate orientation for imaging. Animals in the cross-sectional group 
analysis of the humanized anti-CD4 fragment received an average dose of 6.04 mCi (4.01–8.23 mCi) of 99mTc-
F(ab′)2-OKT4A as described in Supplemental Table 1 Animals in the cross-sectional group analysis of the rhesus 
recombinant anti-CD4 fragment received an average dose of 6.12 mCi (4.34–9.04 mCi) of 99mTc-F(ab′)2-CD4R1 
as described in Supplemental Table 1. Animals in the longitudinal cART-group analysis were imaged at multiple 
time points as described in Supplemental Tables 1 and 2. Serial scintillation camera images were acquired with 
a triple-headed SPECT camera (Triad88, Trionix) or a dual-headed SPECT-CT camera (Symbia T2, SPECT/
CT Siemens), at 4 and (in a subgroup of animals) at 19 hours p.r.i. The images were obtained with a low-ener-
gy high-resolution (LEHR) collimator. Individual anterior whole-body images and whole-body SPECT images 
were recorded for visual and semiquantitative analyses of radiotracer uptakes. All images were interpreted by 
an experienced nuclear medicine physician. SPECT images were analyzed by manually drawing consecutive 
ROI over the transverse sections of the heart; liver; kidney; bone marrow (positioned over the head and proxi-
mal segment of the humerus); thymus; submandibular, axillary, and inguinal LNs; and the spleen to cover the 
entire volume of the organs (VOI). The VOI for the submandibular LNs may also include the salivary glands. 
The coregistration of CT and SPECT images was produced in animals imaged with the Symbia T2 (SPECT/
CT) camera and was used to confirm the VOI of the above organs. Semiquantitative analysis of SPECT images 
was performed on SPECT (3D-reconstructed) and whole-body images obtained at 4 hour p.r.i., to estimate the 
relative uptake of radiotracers in different organs. Images were not corrected for partial volume effect (PVE). 
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The radiotracer uptake, also called radiotracer retention, for each VOI was obtained from the maximum activity 
in the VOI normalized on the maximum activity in the liver. In addition, hepatic and other tissue radiotracer 
uptakes were measured as standardized uptake value (SUVmax = [C/ID] × w) from the SPECT images (1), where 
C is the decay-corrected maximum counts converted in μCi/ml using the imaging standard in the VOI, and ID 
and w are the injected dose (expressed in mCi) and body weight (expressed in Kg), respectively. The relative 
radiotracer retention in LTs was calculated with respect to the mean levels measured in a group of healthy con-
trols with CD4+ T cell counts > 600 cells/μl. At the end of each imaging study, 500 μl of blood was withdrawn 
for plasma radioactivity counting in the γ counter. The plasma SUV was derived multiplying the percentage of  
injected dose by the animal weight.
Specificity of binding in vivo
Specificity of  binding in vivo was tested in axillary, inguinal, and submandibular LNs extracted from 2 
animals at 6 hours following 99mTc-F(ab′)2-CD4R1 injection or from 1 monkey at 19 hours after the admin-
istration of  the (99mTc-F(ab′)2-OKT4A) radiotracer. LNs were mechanically disrupted by pressing
 through 
a 70-μm pore–size cell strainer (Thermo Fisher Scientific). Erythrocytes were lysed with ACK lysing buffer 
(BioWhittaker), and cells were washed with complete RPMI medium. Cells were stained with trypan blue 
to obtain the number of  total viable cells. CD4+ cells were isolated using Miltenyi MiniMACS Separator 
(Miltenyi Biotec), per manufacturer’s instructions. Isolated cells were resuspended in 1 ml of  PBS, and the 
radioactivity was counted in the γ counter.
Two additional groups of  2 animals each were euthanized at 6 hours and 21 hours, following 99mTc-
F(ab′)2-CD4R1, and large sections of  the jejunum and colon — as well as of  other organs — were harvest-
ed, placed on a tray, and imaged with the SPECT camera. Small aliquots of  these organs were also counted 
with the γ counter. Each group consisted of  1 healthy and 1 SIV-infected animal with high and low PB 
CD4+ T cell count, respectively. The SIV-infected animal necropsied at 21 hours p.r.i. was also administered 
an anti-CD3 immunotoxin to further deplete the CD4 pool in tissues (32). These animals also underwent 
axillary and rectal mucosal biopsies at 3 hours p.r.i.
Immunogenicity assays
Plasmas at each imaging time point were screened for antibodies to the probe by 3 independent assay, and 
data were excluded from the analyses if  animals developed an anti-CD4 immune response. Three indepen-
dent assays were performed to assess immunogenicity: radio-HPLC analysis, MT4 cell binding assay with 
plasma preincubated with the radiotracer, and ELISA. Aliquots of  99mTc-F(ab′)2-OKT4A or 
99mTc-F(ab′)2-
CD4R1 were incubated in monkey plasma to reach concentration similar to plasma concentration at 4 hours 
p.r.i. (~ 0.1 ng/μl) for 30 minutes at 37°C in a humidified 5% CO2 incubator. Aliquots (each 100 μl) of  incu-
bated samples were analyzed by size-exclusion HPLC equipped with an on-line flow radioactivity detector 
as described above. Another aliquot (20 μl) of  the radiotracer-plasma incubation mixture was dispensed in 
2 million MT4 cells for plasma cell binding assay for 90 minutes at 4°C. After incubation, the wells were 
washed, and the percentage of  total activity bound to cells was determined in the γ counter (Wizard). The 
presence of  anti-Ig responses directed against the anti-CD4 in the plasmas of  rhesus monkeys was also 
determined by ELISA using 96-well plates coated with the parent CDR-OKT4A/huIgG4 or its digested 
F(ab′)2-OKT4A. A secondary mouse anti–human λ light chain conjugated to biotin (Miltenyi Biotec) and 
streptavidin/HRP system was used to detect binding of  monkey IgG to the immobilized antigens. ELISA 
plates were washed to remove unbound detection antibodies, followed by incubation with tetramethylbenzi-
dine (TMB) as a substrate. Enzymatic products were measured by an ELISA plate reader at 450 nm. Positive 
detection is defined as OD that is at least twice the baseline value (preradiotracer injection).
Statistics
Linear mixed effect models, accounting for repeated measures by a random intercept per animal, were used 
for all the longitudinal analyses. One-tailed greater-than Spearman rank correlation test (using Winstat) 
was used to assess the relationship between variables in cross-sectional analyses; Wilcoxon rank sum tests 
were used to compare groups in Figure 2, when animals had repeated measurements (around the same 
time point used in the cross-sectional analysis). One measurement was selected for each animal. The total 
number of  possible combinations for this selection process was used to obtain a P value for comparison as 
described in ref. 33. Other analyses were performed in R (34); mixed-effects modeling for the longitudinal 
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analysis used the Lme4 and lmerTest packages (35, 36). A linear generalized estimating equation, with 
small sample size adjusted, was used to calculate means and robust 95% CI when there were repeated mea-
surements for the same time point for any of  the animals (GEE and SAWS packages in R; refs. 4, 5). P < 
0.05 was considered statistically significant.
Study approval
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of  Laboratory Animals (National Academies Press, 2011).
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